• 1. An amorphous carbon nitride/NiO/CoN-based composite: a highly efficient nonprecious electrode for supercapacitors and the oxygen evolution reaction?
  Huifang Yang,Haoran Guo,Peidong Fan,Xinpan Li,Wenlu Ren,Rui Song Nanoscale, 2020,12, 7024-7034
• 2. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 3. An amide probe as a selective Al3+ and Fe3+ sensor inside the HeLa and a549 cell lines: Pictet–Spengler reaction for the rapid detection of tryptophan amino acid?
  Bidyut Kumar Kundu,Rinky Singh,Ritudhwaj Tiwari,Debasis Nayak New J. Chem., 2019,43, 4867-4877
• 4. An antioxidant self-healing hydrogel for 3D cell cultures?
  Lei Yang,Yuan Zeng,Haibo Wu,Chunwu Zhou,Lei Tao J. Mater. Chem. B, 2020,8, 1383-1388
• 5. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli

Recent Advances in the Application of (2-Chloro-3-fluoro-5-methylpyridin-4-yl)boronic Acid (CAS: 1072952-39-6) in Chemical Biology and Pharmaceutical Research

(2-Chloro-3-fluoro-5-methylpyridin-4-yl)boronic acid (CAS: 1072952-39-6) has emerged as a crucial building block in medicinal chemistry and drug discovery, particularly in the development of kinase inhibitors and proteolysis-targeting chimeras (PROTACs). Recent studies have highlighted its unique structural features that enable selective binding to various biological targets. The presence of both boronic acid and halogenated pyridine moieties makes this compound particularly valuable for Suzuki-Miyaura cross-coupling reactions, a cornerstone in modern pharmaceutical synthesis.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the compound's utility in developing novel Bruton's tyrosine kinase (BTK) inhibitors. Researchers utilized 1072952-39-6 as a key intermediate to create a series of potent and selective inhibitors showing promise for treating B-cell malignancies. The electron-withdrawing effects of the chloro and fluoro substituents were found to significantly enhance the compound's reactivity in palladium-catalyzed coupling reactions, while the boronic acid group facilitated efficient bioconjugation.

In the field of targeted protein degradation, a recent Nature Chemical Biology publication (2024) reported the successful incorporation of (2-chloro-3-fluoro-5-methylpyridin-4-yl)boronic acid into heterobifunctional PROTAC molecules. The compound's unique steric and electronic properties enabled the development of cereblon-based degraders with improved pharmacokinetic profiles. Particularly noteworthy was the compound's ability to maintain stability in physiological conditions while allowing efficient target engagement, addressing a common challenge in PROTAC development.

From a synthetic chemistry perspective, advances in the preparation of 1072952-39-6 have been significant. A 2023 Organic Process Research & Development paper detailed an optimized large-scale synthesis route that improved yield from 42% to 78% while reducing palladium catalyst loading. This development has important implications for the commercial availability of this valuable building block, potentially lowering costs for pharmaceutical developers.

The compound's application extends beyond small molecule therapeutics. Recent work published in Bioconjugate Chemistry (2024) demonstrated its use in antibody-drug conjugate (ADC) development. The boronic acid moiety allowed for stable conjugation to monoclonal antibodies via oxime formation, while the halogenated pyridine structure contributed to the overall hydrophobicity balance of the resulting ADC, a critical factor in drug delivery efficiency.

Looking forward, researchers are exploring the potential of 1072952-39-6 in covalent inhibitor design, leveraging the reactivity of both the boronic acid group and the halogen substituents. Preliminary results presented at the 2024 ACS Spring Meeting suggest promising applications in targeting cysteine residues in challenging drug targets. As the field of chemical biology continues to evolve, (2-chloro-3-fluoro-5-methylpyridin-4-yl)boronic acid is poised to remain a versatile tool in medicinal chemistry and drug discovery efforts.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)